Free tool
FAERS Monitor: Adquey
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219474 or its brand name (Adquey, Difamilast). Reports on generic versions are filed under their own applications.
Reports
11
Serious
9
82% of reports
Hospitalization
4
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vomiting2
- blister1
- chills1
- cough1
- cutaneous t-cell lymphoma1
- dermatitis atopic1
- eczema herpeticum1
- eczema nummular1
- erythema1
- erythema multiforme1
- feeding disorder1
- metapneumovirus bronchitis1
- no adverse event1
- pigmentation disorder1
- pruritus1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,148 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| metapneumovirus bronchitis | 1 | 957006.7 | 93427.9 | 159,500 |
| eczema herpeticum | 1 | 4142.9 | 637.9 | 1,033 |
| eczema nummular | 1 | 3922.2 | 604.0 | 978 |
| cutaneous t-cell lymphoma | 1 | 1520.3 | 234.4 | 379 |
| pigmentation disorder | 1 | 309.7 | 47.8 | 76 |
| erythema multiforme | 1 | 205.0 | 31.6 | 50 |
| feeding disorder | 1 | 94.3 | 14.5 | 23 |
| dermatitis atopic | 1 | 36.3 | 5.6 | 8 |
| blister | 1 | 34.0 | 5.3 | 8 |
| chills | 1 | 16.3 | 2.5 | 3 |
| no adverse event | 1 | 10.6 | 1.6 | 2 |
| erythema | 1 | 9.3 | 1.4 | 1 |
| vomiting | 2 | 8.1 | 2.3 | 7 |
| cough | 1 | 6.8 | 1.1 | 1 |
| pruritus | 1 | 5.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.